Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia

Br J Haematol. 2018 Sep;182(6):927-930. doi: 10.1111/bjh.14884. Epub 2017 Aug 2.

Authors

Abraham M Varghese¹, Andy Rawstron², Darren Newton³, Reuben M Tooze³, Talha Munir¹, Marion Dickson⁴, Gina M Doody³, Peter Hillmen¹

Affiliations

¹ Department of Haematology, St. James's University Hospital, Leeds, UK.
² Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, UK.
³ Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
⁴ Immunoinflammation Therapy Area, GlaxoSmithKline, Stevenage, UK.

PMID: 28770560
DOI: 10.1111/bjh.14884

No abstract available

Publication types

Letter

MeSH terms

Aniline Compounds / pharmacology
Aniline Compounds / therapeutic use*
Calcium Signaling / drug effects
Cell Survival / drug effects
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Phosphorylation / drug effects
Pyrimidines / pharmacology
Pyrimidines / therapeutic use*
Syk Kinase / antagonists & inhibitors
Syk Kinase / metabolism
Tumor Cells, Cultured

Substances

Aniline Compounds
GSK143
Pyrimidines
SYK protein, human
Syk Kinase